AAC: ADP/ATP provider; mtNDPK: mitochondrial nucleoside diphosphate kinase; mtNMPK: mitochondrial nucleoside monophosphate kinase; TCA cycle: tricarboxylic acid cycle; UCP: uncoupling protein; ?: possibly direct inhibition. Representative references are cited. To assess the key benefits of SU9516

The primary limitation of our analyze was The shortcoming to check a PD-one/PD-L1 inhibitor in combination with S and S+R due to unavailability of the rat cross reactive antibody. However, we did clearly show PD-L1 upregulation on- or article- treatment method with S and S+R that's why substanti